Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | USP30 | Q70CQ3 | 11/20 | 1.00 |
| ▸ | HDAC4 | P56524 | 2/20 | 0.47 |
| ▸ | HDAC6 | Q9UBN7 | 2/20 | 0.47 |
| ▸ | PARP1 | P09874 | 1/20 | 0.44 |
| ▸ | ANO1 | Q5XXA6 | 1/20 | 0.42 |
| ▸ | CCNC | P24863 | 1/20 | 0.41 |
| ▸ | CDK8 | P49336 | 1/20 | 0.41 |
| ▸ | HASPIN | Q8TF76 | 1/20 | 0.41 |
| ▸ | DGAT1 | O75907 | 1/20 | 0.41 |
| ▸ | FPR3 | P25089 | 1/20 | 0.41 |
| ▸ | FPR2 | P25090 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23585212 | 1.00 | USP30 (1.00) | USP30HDAC4HDAC6PARP1ANO1 | |
| SCHEMBL18124163 | 1.00 | USP30 (1.00) | USP30HDAC4HDAC6PARP1ANO1 | |
| SCHEMBL21371903 | 0.88 | USP30 (0.78) | USP30HDAC4HDAC6PARP1ANO1 | |
| SCHEMBL18115860 | 0.87 | USP30 (0.76) | USP30DGAT1 | |
| SCHEMBL19990896 | 0.87 | USP30 (0.76) | USP30DGAT1 | |
| SCHEMBL23019647 | 0.83 | USP30 (0.70) | USP30HDAC4HDAC6DGAT1 | |
| SCHEMBL23019729 | 0.81 | USP30 (0.68) | USP30HDAC4HDAC6PARP1 | |
| SCHEMBL18124205 | 0.81 | USP30 (0.68) | USP30HDAC4HDAC6PARP1 | |
| SCHEMBL29779120 | 0.81 | USP30 (0.68) | USP30HDAC4HDAC6PARP1 | |
| SCHEMBL18124157 | 0.81 | USP30 (0.69) | USP30HDAC4HDAC6PARP1ANO1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12637426-B2 | 1-cyano-pyrrolidine compounds as USP30 inhibitors | MISSION THERAPEUTICS LIMITED (GB) | 2026-05-26 | — | — | US | disclosed |
| US-20220251041-A1 | 1-CYANO-PYRROLIDINE COMPOUNDS AS USP30 INHIBITORS | MISSION THERAPEUTICS LTD (GB) | 2022-08-11 | — | — | US | disclosed |
| US-11390584-B2 | 1-cyano-pyrrolidine compounds as USP30 inhibitors | MISSION THERAPEUTICS LIMITED (GB) | 2022-07-19 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220251041-A1 | 1-CYANO-PYRROLIDINE COMPOUNDS AS USP30 INHIBITORS | USP30, USP20, USP10 | USP30 1/4885HDAC4 2270/4885HDAC6 378/4885 |
| US-12637426-B2 | 1-cyano-pyrrolidine compounds as USP30 inhibitors | USP30, USP1, USP10 | USP30 1/4885HDAC4 1698/4885HDAC6 242/4885 |
| US-11390584-B2 | 1-cyano-pyrrolidine compounds as USP30 inhibitors | USP30, USP20, USP10 | USP30 1/4885HDAC4 2163/4885HDAC6 379/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.